Botulinum Toxin A Improves the Quality of Life of Patients with Neurogenic Urinary Incontinence

European Urology

Volumn 52, Issue 3, 2007, Pages 850-859

  Schurch, Brigitte ^a   Denys, Pierre ^b   Kozma, Chris M ^c   Reese, Pat Ray ^d   Slaton, Terra ^c   Barron, Richard L ^e  

^a BALGRIST UNIVERSITY HOSPITAL   (Switzerland)

^b RAYMOND POINCARÉ HOSPITAL   (France)

^c UNIVERSITY OF SOUTH CAROLINA   (United States)

^d Reese Associates Consulting LLC   (United States)

^e ALLERGAN INC   (United States)

Author keywords

Botulinum toxin type A; I QOL; Neurogenic urinary incontinence; Quality of life; Validity

Indexed keywords

BOTULINUM TOXIN A; OXYBUTYNIN; PLACEBO; TOLTERODINE;

ADULT; AGED; ARTICLE; AVOIDANCE LIMITING BEHAVIOR SUBSCALE; BELGIUM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DETRUSOR MUSCLE; DOUBLE BLIND PROCEDURE; FEMALE; FRANCE; HUMAN; INCONTINENCE QUALITY OF LIFE QUESTIONNAIRE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NEUROGENIC BLADDER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOSOCIAL IMPACT AND SOCIAL EMBARRASSMENT SUBSCALE; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SINGLE DRUG DOSE; SPINAL CORD INJURY; SWITZERLAND; TREATMENT DURATION; TREATMENT OUTCOME; URINE INCONTINENCE; VALIDITY;

ADULT; AGED; BOTULINUM TOXIN TYPE A; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME; URINARY BLADDER; URINARY BLADDER, NEUROGENIC;

EID: 34547187166     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2007.04.026     Document Type: Article

References (25)

1. Borello-France D., Leng W., O'Leary M., et al. Bladder and sexual function among women with multiple sclerosis. Mult Scler 10 (2004) 455-461
2. Hicken B.L., Putzke J.D., and Richards J.S. Bladder management and quality of life after spinal cord injury. Am J Phys Med Rehabil 80 (2001) 916-922
3. Denys P., Corcos J., Everaert K., et al. Improving the global management of the neurogenic bladder patient. Part I. The complexity of patients. Curr Med Res Opin 22 (2006) 359-365
4. Schurch B., de Seze M., Denys P., et al. Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 174 (2005) 196-200
5. Lubeck D.P., Prebil L.A., Peeples P., and Brown J.S. A health related quality of life measure for use in patients with urge urinary incontinence: a validation study. Qual Life Res 8 (1999) 337-344
6. Wagner T.H., Patrick D.L., Bavendam T.G., Martin M.L., and Buesching D.P. Quality of life of persons with urinary incontinence: development of a new measure. Urology 47 (1996) 67-71 discussion 71-2
7. Chiaffarino F., Parazzini F., Lavezzari M., and Giambanco V. Impact of urinary incontinence and overactive bladder on quality of life. Eur Urol 43 (2003) 535-538
8. Patrick D.L., Martin M.L., and Bushnell D.M. The I-QOL: A quality of life instrument specific to persons with urinary incontinence: user's manual and scoring diskette for United States version (1999), Health Research Associates, Inc., Seattle, WA
9. Schurch B, Denys P, Kozma CM, Reese PR, Slaton T, Barron R. The reliability, validity and impact of the use of the Incontinence Quality of Life questionnaire in patients with neurogenic urinary incontinence: validation of the measure and evaluation of the impact of botulinum toxin type A (BoNTA) treatment. Arch Phys Med Rehabil. In press.
10. Bagi P., and Biering-Sorensen F. Botulinum toxin A for treatment of neurogenic detrusor overactivity and incontinence in patients with spinal cord lesions. Scand J Urol Nephrol 38 (2004) 495-498
11. Grosse J., Kramer G., and Stöhrer M. Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 47 (2005) 653-659
12. Hajebrahimi S., Altaweel W., Cadoret J., Cohen E., and Corcos J. Efficacy of botulinum-A toxin in adults with neurogenic overactive bladder: initial results. Can J Urol 12 (2005) 2543-2546
13. Naughton M.J., Donovan J., Badia X., et al. Symptom severity and QOL scales for urinary incontinence. Gastroenterology 126 (2004) S114-S123
14. Guyatt G.H., Bombardier C., and Tugwell P.X. Measuring disease-specific quality of life in clinical trials. CMAJ 134 (1986) 889-895
15. Kalsi V., Apostolidis A., Popat R., Gonzales G., Fowler C.J., and Dasgupta P. Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. Eur Urol 49 (2006) 528-535
16. Flynn M.K., Webster G.D., and Amundsen C.L. The effect of botulinum-A toxin on patients with severe urge urinary incontinence. J Urol 172 (2004) 2316-2320
17. Patki P.S., Hamid R., Arumugam K., Shah P.J., and Craggs M. Botulinum toxin-type A in the treatment of drug-resistant neurogenic detrusor overactivity secondary to traumatic spinal cord injury. BJU Int 98 (2006) 77-82
18. Ghei M., Maraj B.H., Miller R., et al. Effects of botulinum toxin B on refractory detrusor overactivity: a randomized, double-blind, placebo controlled, crossover trial. J Urol 174 (2005) 1873-1877 discussion 1877
19. Hay-Smith J, Herbison P, Ellis G, Morris A. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev 2005:CD005429.
20. Herbison P., Hay-Smith J., Ellis G., and Moore K. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ 326 (2003) 841-844
21. Kelleher C.J., Cardozo L., Chapple C.R., Haab F., and Ridder A.M. Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU Int 95 (2005) 81-85
22. Diokno A., Sand P., Labasky R., et al. Long-term safety of extended-release oxybutynin chloride in a community-dwelling population of participants with overactive bladder: a one-year study. Int Urol Nephrol 34 (2002) 43-49
23. Bushnell D.M., Martin M.L., Summers K.H., Svihra J., Lionis C., and Patrick D.L. Quality of life of women with urinary incontinence: cross-cultural performance of 15 language versions of the I-QOL. Qual Life Res 14 (2005) 1901-1913
24. Patrick D.L., Martin M.L., Bushnell D.M., Yalcin I., Wagner T.H., and Buesching D.P. Quality of life of women with urinary incontinence: further development of the incontinence quality of life instrument (I-QOL). Urology 53 (1999) 71-76
25. Lee J., Barron R., and Patrick D. Qualitative assessment of content validity of the incontinence quality of life questionnaire (I-QOL) in neurogenic patients (spinal cord injury and MS). Qual Life Res 14 (2005) 2007